A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy

Trial Profile

A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs MT 3995 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Feb 2014 Planned number of patients changed from 30 to 45 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top